Targacept, Inc.Conference Call To Discuss Results of Phase 2b clinical trial of TC-5619 Today's Calls 
Visit the TF Network Sites
Visit the TF Network Sites
· Corporate IR Center
· Institutional Investor Center
· Individual Investor Center
Download Plug-In
Real Player 8 Basic
Windows Media Player
Other Conference Calls
Other Dec 17 Calls
Today's Calls
Call Details
Targacept, Inc.Conference Call To Discuss Results of Phase 2b clinical trial of TC-5619
Scheduled to start Tue, Dec 17, 2013, 8:45 am Eastern

-- this event is ongoing now--
Listen to the ongoing live event audio stream

About Targacept Inc (NasdaqGS:TRGT)
Targacept, Inc., a biopharmaceutical company, engages in the development of neuronal nicotinic receptors (NNR) therapeutics for the treatment of diseases and disorders of the nervous system. Its product candidates include TC-5619 that is in Phase IIb clinical trial for the treatment of negative symptoms and cognitive dysfunction in schizophrenia; TC-5214 to treat overactive bladder; and TC-1734, which is in Phase IIb clinical trial for the treatment of mild to moderate Alzheimer’s disease. The company’s product candidates also comprise TC-6499 for the treatment for gastrointestinal disorders; TC-6987, a novel small molecule that modulates the activity of the a7 NNR; and AZD1446 (TC-6683), a novel small molecule that modulates the activity of the a4ß2 NNR. It has a collaboration agreement with AstraZeneca AB to develop AZD1446 and earlier-stage compounds. Targacept, Inc. was founded in 1997 and is based in Winston-Salem, North Carolina.


More Info: Quote | Profile | Reports | Research | Msgs | Insider | Financials | Analyst Ratings


Copyright © 2013 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Copyright © 2013 FirstCall Events. Historical chart data provided by Commodity Systems, Inc. (CSI). Company profile information presented on this page is Copyright Capital IQ. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.